CREATE Medicines to Present Late-Breaking Clinical Data on MT-302 at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

CREATE Medicines, Inc. (formerly Myeloid Therapeutics), a clinical-stage biotech pioneering in vivo multi-immune programming, today announced that clinical results from its Phase 1 MYE Symphony trial ...

Moderna Announces First Patient Dosed in Phase 1/2 Study of Investigational T-Cell Engager for Multiple Myeloma

CAMBRIDGE, MA / ACCESS Newswire / / Moderna, Inc. (NASDAQ:MRNA) today announced that the first patient has been dosed in a Phase 1/2 study of mRNA-2808, the Company's investigational mRNA-based T-cell ...
Bizcommunity

Aspen Pharmacare reaches €25m settlement in mRNA contract dispute

Aspen Pharmacare said it had reached a €25m settlement in a contractual dispute with a client over a manufacturing and ...